CA3246440A1 - BICYCLIC TRIAZINE DERIVATIVES FOR TREATING CANCER - Google Patents

BICYCLIC TRIAZINE DERIVATIVES FOR TREATING CANCER

Info

Publication number
CA3246440A1
CA3246440A1 CA3246440A CA3246440A CA3246440A1 CA 3246440 A1 CA3246440 A1 CA 3246440A1 CA 3246440 A CA3246440 A CA 3246440A CA 3246440 A CA3246440 A CA 3246440A CA 3246440 A1 CA3246440 A1 CA 3246440A1
Authority
CA
Canada
Prior art keywords
trifluoromethyl
salt
cancer
triazin
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3246440A
Other languages
English (en)
French (fr)
Inventor
Kai Thede
Philipp BUCHGRABER
Gerhard Siemeister
Patrick STEIGEMANN
Antje Margret Wengner
Ulf Bomer
Philip Lienau
Frank Westermann
Hanno Glimm
Friederike HERBST-NOWROUZI
Sebastian DIETER
Sina KRETH
Original Assignee
Deutsches Krebsforschungszentrum DKFZ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Deutsches Krebsforschungszentrum DKFZ filed Critical Deutsches Krebsforschungszentrum DKFZ
Publication of CA3246440A1 publication Critical patent/CA3246440A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3246440A 2022-01-11 2023-01-06 BICYCLIC TRIAZINE DERIVATIVES FOR TREATING CANCER Pending CA3246440A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP22150829 2022-01-11
EP22150829.4 2022-01-11
PCT/EP2023/050208 WO2023135057A1 (en) 2022-01-11 2023-01-06 Bicyclic triazine derivatives for the treatment of cancer

Publications (1)

Publication Number Publication Date
CA3246440A1 true CA3246440A1 (en) 2023-07-20

Family

ID=79927598

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3246440A Pending CA3246440A1 (en) 2022-01-11 2023-01-06 BICYCLIC TRIAZINE DERIVATIVES FOR TREATING CANCER

Country Status (9)

Country Link
US (1) US20250066370A1 (https=)
EP (1) EP4463458A1 (https=)
JP (1) JP2025502240A (https=)
KR (1) KR20240134962A (https=)
CN (1) CN118541372A (https=)
AU (1) AU2023207765A1 (https=)
CA (1) CA3246440A1 (https=)
IL (1) IL313835A (https=)
WO (1) WO2023135057A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021176045A1 (en) * 2020-03-06 2021-09-10 Bayer Aktiengesellschaft Imidazotriazines acting on cancer via inhibition of cdk12

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011529072A (ja) 2008-07-24 2011-12-01 セラヴァンス， インコーポレーテッド 二重作用血圧降下薬
US8791162B2 (en) 2011-02-14 2014-07-29 Merck Sharp & Dohme Corp. Cathepsin cysteine protease inhibitors
MX2019012431A (es) 2017-04-21 2020-08-03 Ikena Oncology Inc Inhibidores del receptor de hidrocarburos de arilo (ahr) de indol y usos de los mismos.
TW202146416A (zh) 2019-12-11 2021-12-16 德商拜耳廠股份有限公司 吡唑并三𠯤
WO2021176045A1 (en) 2020-03-06 2021-09-10 Bayer Aktiengesellschaft Imidazotriazines acting on cancer via inhibition of cdk12
WO2021176049A1 (en) 2020-03-06 2021-09-10 Bayer Aktiengesellschaft Pyrazolopyrazines acting on cancers via inhibition of cdk12

Also Published As

Publication number Publication date
KR20240134962A (ko) 2024-09-10
WO2023135057A1 (en) 2023-07-20
EP4463458A1 (en) 2024-11-20
CN118541372A (zh) 2024-08-23
JP2025502240A (ja) 2025-01-24
AU2023207765A1 (en) 2024-07-04
US20250066370A1 (en) 2025-02-27
IL313835A (en) 2024-08-01

Similar Documents

Publication Publication Date Title
EP3532474B1 (en) 4,5-annulated 1,2,4-triazolones
EP3661517B1 (en) Dihydrooxadiazinones
WO2018024602A1 (en) 2,7-diazaspiro[4.4]nonanes
EP3710456B1 (en) Macrocyclic indole derivatives
EP4114528A1 (en) Imidazotriazines acting on cancer via inhibition of cdk12
EP3390387B1 (en) Heteroarylbenzimidazole compounds
EP4229045A1 (en) Substituted acyl sulfonamides for treating cancer
WO2021116178A1 (en) Pyrazolotriazines
US20240279207A1 (en) Substituted acyl sulfonamides for treating cancer
US20250170136A1 (en) 1,2,4-triazin-3(2h)-one compounds for the treatment of hyperproliferative diseases
WO2021176049A1 (en) Pyrazolopyrazines acting on cancers via inhibition of cdk12
CA3246440A1 (en) BICYCLIC TRIAZINE DERIVATIVES FOR TREATING CANCER
WO2017207534A1 (en) Substituted heteroarylbenzimidazole compounds
EP3555075A1 (en) [4-(phenylsulfonyl)piperazin-1-yl](1h-1,2,3-triazol-4-yl)methanones
HK40085534A (en) Imidazotriazines acting on cancer via inhibition of cdk12
WO2020157236A1 (en) Pyridyl substituted dihydrooxadiazinones
WO2018114672A1 (en) [4-(phenylsulfonyl)piperazin-1-yl](1h-1,2,3-triazol-4-yl)methanones
WO2018114677A2 (en) [(phenylsulfonyl)octahydro-epiminoisoindol-yl](1h-1,2,3-triazol-5-yl)methanones

Legal Events

Date Code Title Description
A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT

Effective date: 20240703

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

A15 Pct application entered into the national or regional phase

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20241127

P18 Priority claim added or amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20241127

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20241127

A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET

Effective date: 20241219

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-P146 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: BSL VERIFIED - NO DEFECTS

Effective date: 20241219

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251224

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251224